

Fang-Shu Ou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7787825/publications.pdf>

Version: 2024-02-01

63
papers

3,212
citations

430874

18
h-index

161849

54
g-index

63
all docs

63
docs citations

63
times ranked

6059
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139. | 13.7 | 1,487 |
| 2 | Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. <i>Journal of Clinical Oncology</i> , 2019, 37, 1217-1227. | 1.6 | 234 |
| 3 | ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal“Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770. | 27.6 | 218 |
| 4 | Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2019, 20, 1070-1082. | 10.7 | 169 |
| 5 | Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). <i>Journal of Clinical Oncology</i> , 2019, 37, 1876-1885. | 1.6 | 169 |
| 6 | Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. <i>BMC Cancer</i> , 2017, 17, 505. | 2.6 | 166 |
| 7 | Biomarker Discovery and Validation: Statistical Considerations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 537-545. | 1.1 | 66 |
| 8 | Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 631-641. | 1.6 | 63 |
| 9 | Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient“Level Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018, 36, 2593-2602. | 1.6 | 59 |
| 10 | Randomized Phase II Study of PET Response“Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2803-2815. | 1.6 | 58 |
| 11 | Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631. | 1.6 | 51 |
| 12 | Primary (1€) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3503-3503. | 1.6 | 49 |
| 13 | Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040. | 5.9 | 48 |
| 14 | Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505. | 7.0 | 44 |
| 15 | Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713. | 7.1 | 24 |
| 16 | Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435. | 6.3 | 24 |
| 17 | Marine omega–3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). <i>International Journal of Cancer</i> , 2019, 145, 380-389. | 5.1 | 22 |
| 18 | Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078. | 2.9 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751. | 1.6 | 20 |
| 20 | Perioperative Gemcitabine+ Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 4489-4497. | 1.5 | 19 |
| 21 | Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. <i>European Journal of Cancer</i> , 2019, 111, 82-93. | 2.8 | 17 |
| 22 | Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1227-1230. | 2.5 | 15 |
| 23 | Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021, 27, 267-275. | 7.0 | 13 |
| 24 | Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). <i>European Journal of Cancer</i> , 2021, 150, 214-223. | 2.8 | 12 |
| 25 | Guidelines for Statistical Reporting in Medical Journals. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1722-1726. | 1.1 | 10 |
| 26 | Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024. | 2.9 | 8 |
| 27 | Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. <i>JAMA Network Open</i> , 2020, 3, e2023500. | 5.9 | 8 |
| 28 | The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. <i>Translational Oncology</i> , 2021, 14, 100973. | 3.7 | 8 |
| 29 | Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). <i>Endocrine-Related Cancer</i> , 2022, 29, 335-344. | 3.1 | 8 |
| 30 | Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. <i>Oncogene</i> , 2022, 41, 260-267. | 5.9 | 7 |
| 31 | Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. <i>Clinical Cancer Research</i> , 2022, 28, 1690-1700. | 7.0 | 7 |
| 32 | IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074. | 2.9 | 6 |
| 33 | Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). <i>Cancer</i> , 2021, 127, 3801-3808. | 4.1 | 6 |
| 34 | Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3535-3535. | 1.6 | 6 |
| 35 | Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3599-3599. | 1.6 | 6 |
| 36 | Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100492. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1692-1695. | 2.5 | 5 |
| 38 | Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016, 128, 3027-3027. | 1.4 | 5 |
| 39 | Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). <i>Oncologist</i> , 2022, 27, e494-e505. | 3.7 | 5 |
| 40 | Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. <i>Cancer Causes and Control</i> , 2019, 30, 757-765. | 1.8 | 4 |
| 41 | Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021, 5, 1737-1745. | 5.2 | 4 |
| 42 | Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab034. | 2.9 | 4 |
| 43 | Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 193-193. | 1.6 | 4 |
| 44 | Quantile regression models for current status data. <i>Journal of Statistical Planning and Inference</i> , 2016, 178, 112-127. | 0.6 | 3 |
| 45 | Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. <i>Blood</i> , 2016, 128, 1102-1102. | 1.4 | 3 |
| 46 | Predictive and prognostic value of <i>HER2</i> gene expression and <i>HER2</i> amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4086-4086. | 1.6 | 3 |
| 47 | Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. <i>Journal of Geriatric Oncology</i> , 2022, 13, 469-479. | 1.0 | 3 |
| 48 | Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. <i>JAMA Network Open</i> , 2022, 5, e220145. | 5.9 | 3 |
| 49 | FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1228-1240. | 3.0 | 2 |
| 50 | Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 612-612. | 1.6 | 2 |
| 51 | Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. <i>Oncologist</i> , 2022, 27, 292-298. | 3.7 | 2 |
| 52 | Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1117-e1122. | 1.9 | 1 |
| 53 | Milestone prediction for time-to-event endpoint monitoring in clinical trials. <i>Pharmaceutical Statistics</i> , 2019, 18, 433-446. | 1.3 | 1 |
| 54 | Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies. <i>JCO Precision Oncology</i> , 2019, 3, 1-10. | 3.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 4055. | 3.7 | 1 |
| 56 | Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. <i>Blood</i> , 2016, 128, 4196-4196. | 1.4 | 1 |
| 57 | Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-102. | 1.6 | 1 |
| 58 | Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100827. | 1.1 | 0 |
| 59 | Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). <i>Epigenetics</i> , 2022, , 1-11. | 2.7 | 0 |
| 60 | Predictive value of <i>CDC37</i> gene expression for targeted therapy in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3586-3586. | 1.6 | 0 |
| 61 | Predictive value of <i>MAOB</i> gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3580-3580. | 1.6 | 0 |
| 62 | ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4170-TPS4170. | 1.6 | 0 |
| 63 | Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3553-3553. | 1.6 | 0 |